Targets › HMOX1
4 programs from 4 companies in 5 trials: 2 Phase 2, 2 Phase 4, 1 Phase 1; Cardiovascular, Infectious disease, Oncology; next expected readout Dec 2026.
[Heme oxygenase 1]: Catalyzes the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolize free heme and prevent it from sensitizing cells to undergo apoptosis..;…. (UniProt, P09601)
Open in Phaseline: the race on HMOX1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tomsk National Research Medical Center of the Russian Academy of Sciences | Ferinject (ferric carboxymaltose) Iron replacement therapy - ferric carboxymaltose complex for iron deficiency correction | HMOX1 | Phase 4 | Chronic Heart Failure | Dec 2026 |
| Oregon Health and Science University | Iron-Dextran Complex Injection [InFed] Iron replacement therapy for iron-deficiency anemia | HMOX1, FTH1 | Phase 4 | Acute Blood Loss Anemia | – |
| Memorial Sloan Kettering Cancer Center | N-Acetylcysteine (N-AC) Antioxidant; mucolytic agent; precursor to glutathione | HMOX1 | Phase 2 | Covid-19; Lymphoma | May 2027 |
| Aditya S. Pandey, MD | Deferoxamine Iron chelator that binds free iron and prevents free radical formation | HMOX1 | Phase 2 | Aneurysmal Subarachnoid Hemorrhage | Oct 2027 |
Covid-19 (1) Lymphoma (1) Aneurysmal Subarachnoid Hemorrhage (1) Acute Blood Loss Anemia (1) Chronic Heart Failure (1)
small molecule (4)
Memorial Sloan Kettering Cancer Center (1) Aditya S. Pandey, MD (1) Oregon Health and Science University (1) Tomsk National Research Medical Center of the Russian Academy of Sciences (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.